Home > Insider Trading > Filing (0001209191-21-036798)

Filing Details

Accession Number:: 0001209191-21-036798
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-01 16:07:31
Reporting Period:: 2021-05-27

Accepted Time:: 2021-06-01 16:07:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1582313	Xenon Pharmaceuticals Inc.	XENE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
938801	A Frank Holler	200 - 3650 Gilmore Way Burnaby A1 V5G 4W8		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2021-05-27	3,086	$3.76	125,127	No	4	M	Direct
Common Shares	Disposition	2021-05-27	507	$18.88	124,620	No	4	F	Direct
Common Shares	Acquisiton	2021-05-27	36,008	$3.76	160,628	No	4	M	Direct
Common Shares	Disposition	2021-05-27	5,911	$18.88	154,717	No	4	F	Direct
Common Shares	Disposition	2021-05-27	2,579	$18.69	152,138	No	4	S	Direct
Common Shares	Disposition	2021-05-27	8,485	$18.68	143,653	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2021-05-27	3,086	$0.00	3,086	$3.76
Common Shares	Stock Option (Right to Buy)	Disposition	2021-05-27	36,008	$0.00	36,008	$3.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2021-05-28	No	4	M	Direct
0		2021-05-28	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	1,184	Indirect	Spouse

Footnotes

The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Represents the closing price of the Company's common shares on May 26, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.51 to $18.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $18.54 to $18.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.
Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.